Literature DB >> 33946986

PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.

Hong Sheng Cheng1, Yun Sheng Yip1, Eldeen Kai Yi Lim2, Walter Wahli1,3,4, Nguan Soon Tan1,2.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) have been extensively studied for more than three decades. Consisting of three isotypes, PPARα, γ, and β/δ, these nuclear receptors are regarded as the master metabolic regulators which govern many aspects of the body energy homeostasis and cell fate. Their roles in malignancy are also increasingly recognized. With the growing interest in crosstalk between tumor stroma and epithelium, this review aims to highlight the current knowledge on the implications of PPARs in the tumor microenvironment. PPARγ plays a crucial role in the metabolic reprogramming of cancer-associated fibroblasts and adipocytes, coercing the two stromal cells to become substrate donors for cancer growth. Fibroblast PPARβ/δ can modify the risk of tumor initiation and cancer susceptibility. In endothelial cells, PPARβ/δ and PPARα are pro- and anti-angiogenic, respectively. Although the angiogenic role of PPARγ remains ambiguous, it is a crucial regulator in autocrine and paracrine signaling of cancer-associated fibroblasts and tumor-associated macrophages/immune cells. Of note, angiopoietin-like 4 (ANGPTL4), a secretory protein encoded by a target gene of PPARs, triggers critical oncogenic processes such as inflammatory signaling, extracellular matrix derangement, anoikis resistance and metastasis, making it a potential drug target for cancer treatment. To conclude, PPARs in the tumor microenvironment exhibit oncogenic activities which are highly controversial and dependent on many factors such as stromal cell types, cancer types, and oncogenesis stages. Thus, the success of PPAR-based anticancer treatment potentially relies on innovative strategies to modulate PPAR activity in a cell type-specific manner.

Entities:  

Keywords:  cancer-associated adipocyte; cancer-associated fibroblast; metabolic reprogramming; peroxisome proliferation-activated receptor; tumor-associated macrophage

Year:  2021        PMID: 33946986     DOI: 10.3390/cancers13092153

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  170 in total

Review 1.  Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis.

Authors:  Stephanos Pavlides; Iset Vera; Ricardo Gandara; Sharon Sneddon; Richard G Pestell; Isabelle Mercier; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Antioxid Redox Signal       Date:  2011-11-17       Impact factor: 8.401

Review 2.  Peroxisome proliferator-activated receptors and cancer: challenges and opportunities.

Authors:  Jihan Youssef; Mostafa Badr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 3.  Angiopoietin-like 4: a decade of research.

Authors:  Pengcheng Zhu; Yan Yih Goh; Hwee Fang Alison Chin; Sander Kersten; Nguan Soon Tan
Journal:  Biosci Rep       Date:  2012-06       Impact factor: 3.840

4.  Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

Authors:  Kalyani Narra; Stefanie R Mullins; Hyung-Ok Lee; Brenda Strzemkowski-Brun; Kimberly Magalong; Victoria J Christiansen; Patrick A McKee; Brian Egleston; Steven J Cohen; Louis M Weiner; Neal J Meropol; Jonathan D Cheng
Journal:  Cancer Biol Ther       Date:  2007-08-14       Impact factor: 4.742

5.  The combinatory effects of PPAR-γ agonist and survivin inhibition on the cancer stem-like phenotype and cell proliferation in bladder cancer cells.

Authors:  Yang Wang; Hailin Tan; Dongxu Xu; Aihui Ma; Li Zhang; Jiabin Sun; Zhaojuan Yang; Yongzhong Liu; Guowei Shi
Journal:  Int J Mol Med       Date:  2014-05-08       Impact factor: 4.101

6.  Collaborative Regulation of LRG1 by TGF-β1 and PPAR-β/δ Modulates Chronic Pressure Overload-Induced Cardiac Fibrosis.

Authors:  Chenghao Liu; Seok Ting Lim; Melissa Hui Yen Teo; Michelle Si Ying Tan; Madhura Dattatraya Kulkarni; Beiying Qiu; Amy Li; Sean Lal; Cristobal G Dos Remedios; Nguan Soon Tan; Walter Wahli; Michael Alan Ferenczi; Weihua Song; Wanjin Hong; Xiaomeng Wang
Journal:  Circ Heart Fail       Date:  2019-12-13       Impact factor: 8.790

7.  LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.

Authors:  Zhi-Bo Xie; Yi-Fan Zhang; Chen Jin; Yi-Shen Mao; De-Liang Fu
Journal:  J Exp Clin Cancer Res       Date:  2019-02-13

8.  Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4.

Authors:  Ryan Kolb; Paige Kluz; Zhen Wei Tan; Nicholas Borcherding; Nicholas Bormann; Ajaykumar Vishwakarma; Louis Balcziak; Pengcheng Zhu; Brandon Sj Davies; Francoise Gourronc; Ling-Zhi Liu; Xin Ge; Bing-Hua Jiang; Katherine Gibson-Corley; Aloysius Klingelhutz; Nguan Soon Tan; Yuwen Zhu; Fayyaz S Sutterwala; Xian Shen; Weizhou Zhang
Journal:  Oncogene       Date:  2018-12-05       Impact factor: 9.867

Review 9.  Hypoxia and metabolic adaptation of cancer cells.

Authors:  K L Eales; K E R Hollinshead; D A Tennant
Journal:  Oncogenesis       Date:  2016-01-25       Impact factor: 7.485

10.  AMPK contributes to autophagosome maturation and lysosomal fusion.

Authors:  Minsu Jang; Rackhyun Park; Hyunju Kim; Sim Namkoong; Daum Jo; Yang Hoon Huh; Ik-Soon Jang; Jin I Lee; Junsoo Park
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

View more
  7 in total

Review 1.  Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer.

Authors:  Nicole Wagner; Kay-Dietrich Wagner
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

2.  Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.

Authors:  Ke Zhu; Wen Deng; Hui Deng; Xiaoqiang Liu; Gongxian Wang; Bin Fu
Journal:  PPAR Res       Date:  2021-12-30       Impact factor: 4.964

Review 3.  Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights.

Authors:  Bhawna Uprety; Heidi Abrahamse
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

Review 4.  Potential Therapeutic Effects of PPAR Ligands in Glioblastoma.

Authors:  Rossella Basilotta; Marika Lanza; Giovanna Casili; Giulia Chisari; Stefania Munao; Lorenzo Colarossi; Laura Cucinotta; Michela Campolo; Emanuela Esposito; Irene Paterniti
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

Review 5.  Cancer Stem Cells and the Tumor Microenvironment: Targeting the Critical Crosstalk through Nanocarrier Systems.

Authors:  Aadya Nayak; Neerada Meenakshi Warrier; Praveen Kumar
Journal:  Stem Cell Rev Rep       Date:  2022-07-25       Impact factor: 6.692

Review 6.  The Interplay between the Immune and the Endocannabinoid Systems in Cancer.

Authors:  Mariantonia Braile; Simone Marcella; Gianni Marone; Maria Rosaria Galdiero; Gilda Varricchi; Stefania Loffredo
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

Review 7.  Renal Cell Cancer and Obesity.

Authors:  Anna Gluba-Brzózka; Jacek Rysz; Janusz Ławiński; Beata Franczyk
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.